Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02609 佰澤醫療
BAYZED HEALTH
Listing Date2025/06/23    Listing in 3 Days
Listing Price4.220
Grey Market Performance
Last updated: 20/06/2025 19:59  Refresh
  • Bright Smart
    up 5.250 +1.030 (+24.408%)
    High
    5.620
     
    Low
    4.250
    Volume
    238,200
    One Lot Profit
    +618.00
  • Phillip
    up 5.300 +1.080 (+25.592%)
    High
    5.920
     
    Low
    4.500
    Volume
    4,760,000
    One Lot Profit
    +648.00
  • Futu
    up 5.370 +1.150 (+27.251%)
    High
    5.750
     
    Low
    4.520
    Volume
    3,404,400
    One Lot Profit
    +690.00
  • Bid
  • Ask
  • 5.200
  • (1) 1.8K
  • 600 (1)
  • 5.250
  • 5.190
  • (0) 0
  • 0 (0)
  • 5.260
  • 5.180
  • (1) 18K
  • 0 (0)
  • 5.270
  • 5.170
  • (1) 3.6K
  • 0 (0)
  • 5.280
  • 5.160
  • (0) 0
  • 0 (0)
  • 5.290
  • 5.150
  • (0) 0
  • 1.8K (2)
  • 5.300
  • 5.140
  • (0) 0
  • 0 (0)
  • 5.310
  • 5.130
  • (0) 0
  • 0 (0)
  • 5.320
  • 5.120
  • (0) 0
  • 0 (0)
  • 5.330
  • 5.110
  • (0) 0
  • 0 (0)
  • 5.340
  • Bid
  • Ask
  • 5.290
  • (1) 1.8K
  • 5.4K (3)
  • 5.300
  •  
  • (3) 12.6K
  • 30K (2)
  •  
  •  
  • (1) 2.4K
  • 600 (1)
  •  
  •  
  • (1) 600
  • 1.8K (3)
  •  
  •  
  • (2) 1.8K
  • 2.4K (3)
  •  
 
Hide
COMPANY PROFILE

Bayzed Health Group Inc is an oncology healthcare group that principally engages in the investment in, and provision of, medical and healthcare related services in the PRC. The Group is a service provider in the field of full-cycle oncology healthcare services, and screening, diagnosis, treatment and rehabilitation are core services it provided in its full-cycle oncology healthcare services system.

--

According to the report, as of December 31, 2023, the Group ranked the fourth among all private oncology healthcare groups in the PRC in 2023 with corresponding market share of 0.6% in terms of oncology revenue of self-owned hospitals; ranked the first among all private oncology healthcare groups in the PRC in terms of the number of screening and early detection of cancer centers; and ranked the first among all private oncology healthcare groups in the PRC in terms of the number of gastrointestinal endoscopy cases.

--

The Group operated and managed a network of eight hospitals in Beijing, Tianjin, Shanxi Province, Anhui Province and Henan Province with strategic focus on provision of full-cycle oncology healthcare services, through its direct ownership in the equity interest in six private for-profit hospitals and management over two private not-for-profit hospitals.

--

The Group generated revenue primarily from its hospital business, comprising inpatient services, outpatient services and others. The Group’s customers primarily fall into three categories: patients and/or customers that received healthcare services at its self-owned hospitals; Managed Hospital and Health Service Center; and wholesale customers and retail customers.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot600
GLOBAL OFFERING
No. of Offer Shares133.11M shares
No. of International Offer Shares119.79M shares
No. of HK Offer Shares13.31M shares
Offer Price$4.22 - $6.75
Stock Code2609
Sponsor(s)CMB International Capital Limited
Underwriter(s)CMB International Capital Limited, Futu Securities International (Hong Kong) Limited
TIME TABLE
Application PeriodJun 13 (Fri) - noon, Jun 18 (Wed)
Price Determination DateJun 19 (Thu)
Result Announcement DateOn or before Jun 20 (Fri)
Result Announcement DateOn or before Jun 20 (Fri)
Result Announcement DateOn or before Jun 23 (Mon)
Dealings in Shares commence onJun 23, 2025. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$4.22 - $6.75
Capitalization5.56B - 8.90B
NAV / share ($)$0.59 - $0.84 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 5.49, the net proceeds raised would be HKD 623.60M, of which
35.7% : Strengthen full-cycle oncology healthcare services
30.6% : Acquire hospitals when appropriate opportunities arise
15.3% : Expand hospital management business
10.2% : Upgrade IT infrastructure and systems
8.1% : Working capital
IPO NEWS
20/06/2025 18:35
{New Stock}BAYZED HEALTH ends up 25.59% on grey market
20/06/2025 16:20
{New Stock}BAYZED HEALTH up 10.19% at HK$4.65 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.